Delivers Strong 3QFY23 Revenue Growth; Confirms Progress in Pharmaceutical Development Programs
3QFY23 Review BayMedica's best revenue growth quarter yet. InMed's BayMedica subsidiary, which supplies non-psychoactive rare cannabinoid products to the heath & wellness sector, delivered its best revenue quarter yet since being acquired in October 2021. InMed's third quarter for its fiscal year ending June 30, 2023, saw revenue from the rare cannabinoids business surge 120% from the previous quarter and more than triple from the year-ago period, breaking the $1 million barrier for the first time. Growing awareness of the health benefits of rare cannabinoids is coming to the fore...
Water Tower Research is built on the foundation of democratizing information flow. We bridge the growing information gap between companies and investors through our investor engagement strategies and open-access research platform.
Our research analysts are Wall Street veterans with the experience and knowledge to work with companies and investors in tandem. We provide access to the information and content that anchors the due diligence process for both professional money managers and individual investors. We leverage traditional research distribution channels and the best of modern digital strategies and tactics to amplify this information flow globally to engage all categories of investors and stakeholders.
Information flow is the foundation for creating investor awareness, knowledge, and engagement. Our mission is to help companies and investors have the tools they need and achieve their goals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.